Status:
COMPLETED
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period
Lead Sponsor:
Takeda
Conditions:
Plaque Psoriasis
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque psoriasis. Participants will be assigned to one of t...
Detailed Description
The drug being tested in this study is called TAK-279. TAK-279 is being tested to treat people with moderate to severe plaque psoriasis. The study will enroll approximately 1000 patients. Participant...
Eligibility Criteria
Inclusion
- Plaque psoriasis for at least 6 months.
- Moderate to severe disease.
- Candidate for phototherapy or systemic therapy.
Exclusion
- Other forms of psoriasis.
- History of recent infection.
- Prior exposure to TAK-279 or active comparator.
- Other protocol defined inclusion/exclusion criteria apply.
Key Trial Info
Start Date :
November 6 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 7 2025
Estimated Enrollment :
1108 Patients enrolled
Trial Details
Trial ID
NCT06108544
Start Date
November 6 2023
End Date
November 7 2025
Last Update
November 20 2025
Active Locations (217)
Enter a location and click search to find clinical trials sorted by distance.
1
Total Dermatology
Birmingham, Alabama, United States, 35205
2
Cahaba Dermatology Skin Health Center
Hoover, Alabama, United States, 35244-2111
3
Medical Dermatology Specialists
Phoenix, Arizona, United States, 85006-2722
4
Noble Clinical Research
Tucson, Arizona, United States, 85704-7892